About | Ocular Therapeutix

Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s lead product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Corporate Highlights

AXPAXLI™ Promising Data to Date

AXPAXLI has demonstrated proof-of-concept in three Phase 1 trials

De-Risking the Regulatory Pathway

SOL-1 trial for AXPAXLI is being conducted under a Special Protocol Assessment

Targeting Expansive Retinal Vascular Disease Markets

AXPAXLI has expansive market potential in wet AMD and beyond with a target population of 9.2 million in the U.S. alone¹^*

REFERENCE: 1. Downs P. 2023 Retinal Pharmaceuticals Market Report: Global analysis for 2022 to 2028. Market Scope; 2023.

^*These data reflect the total global market for the respective indications. Our market opportunity for such indications reflects a portion of this market